Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Semin Cancer Biol. 2019 Dec 19;65:28–37. doi: 10.1016/j.semcancer.2019.12.005

Table 1.

FDA-Approved Immune Checkpoint Inhibitors

Antibody Target Approved For
Ipilimumab CTLA4 Metastatic Melanoma, Renal Cell Carcinoma, Colorectal Cancer
Nivolumab PD-1 Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin’s Lymphoma, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, and Small Cell Lung Cancer
Pembrolizumab PD-1 Metastatic Melanoma, Non-Small Cell Lung Cancer, Head and Neck Cancer, Hodgkin’s Lymphoma, Urothelial Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Small Cell Lung Cancer, and Esophageal Carcinoma
Atezolizumab PD-L1 Urothelial Carcinoma, Non-Small Cell Lung Cancer, Breast Cancer, and Small Cell Lung Cancer
Avelumab PD-L1 Merkel Cell Carcinoma, Urothelial Carcinoma, and Renal Cell Carcinoma
Durvalumab PD-L1 Urothelial Carcinoma and Non-Small Cell Lung Cancer
Cemiplimab PD-1 Advanced cutaneous squamous cell carcinoma (CSCC)